{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:55:38Z","timestamp":1761519338077,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772865"],"award-info":[{"award-number":["81772865"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.prp.2021.153677","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T22:47:56Z","timestamp":1635547676000},"page":"153677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma"],"prefix":"10.1016","volume":"228","author":[{"given":"Danhui","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9710-6471","authenticated-orcid":false,"given":"Joseph","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guorui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4717","key":"10.1016\/j.prp.2021.153677_bib1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.2992089","article-title":"Amplification of a novel verbB related gene in a human mammary carcinoma","volume":"229","author":"King","year":"1985","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.prp.2021.153677_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/GCO.0000000000000431","article-title":"Advances in targeting HER2-positive breast cancer","volume":"30","author":"Harbeck","year":"2018","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"16","key":"10.1016\/j.prp.2021.153677_bib3","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2021.153677_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.humpath.2007.06.012","article-title":"Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers","volume":"39","author":"Liu","year":"2008","journal-title":"Hum. Pathol."},{"issue":"3","key":"10.1016\/j.prp.2021.153677_bib5","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1245\/s10434-011-2032-5","article-title":"Prognostic value of basal phenotype in HER2-overexpressing breast cancer","volume":"19","author":"Bagaria","year":"2012","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2021.153677_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/his.14091","article-title":"Classification of tumours editorial board. The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"WHO","year":"2020","journal-title":"Histopathology"},{"issue":"20","key":"10.1016\/j.prp.2021.153677_bib7","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of american pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2021.153677_bib8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.prp.2021.153677_bib9","doi-asserted-by":"crossref","first-page":"7104","DOI":"10.18632\/oncotarget.3106","article-title":"Cytokeratin 5\/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer","volume":"6","author":"Martin-Castillo","year":"2015","journal-title":"Oncotarget"},{"issue":"7291","key":"10.1016\/j.prp.2021.153677_bib10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature08987","article-title":"International network of cancer genome projects","volume":"464","author":"International Cancer Genome","year":"2010","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.prp.2021.153677_bib11","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.prp.2021.153677_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"269","key":"10.1016\/j.prp.2021.153677_bib13","doi-asserted-by":"crossref","first-page":"p11","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal"},{"key":"10.1016\/j.prp.2021.153677_bib14","doi-asserted-by":"crossref","unstructured":"Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer nucleic acidsresearch. 2019; (47): D941\u2013D947. https:\/\/cancer.sanger.ac.uk\/cosmic\/.","DOI":"10.1093\/nar\/gky1015"},{"issue":"Pt 1","key":"10.1016\/j.prp.2021.153677_bib15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/S003118200500733X","article-title":"Diagnosing genetically diverse avian malarial infections using mixed-sequence analysis and TA-cloning","volume":"131","author":"P\u00e9rez-Tris","year":"2005","journal-title":"Parasitology"},{"issue":"2","key":"10.1016\/j.prp.2021.153677_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs working group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2021.153677_bib17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.prp.2021.153677_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13058-018-0933-y","article-title":"HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors","volume":"20","author":"Daemen","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2021.153677_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10549-010-1078-6","article-title":"Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers","volume":"128","author":"Kabos","year":"2011","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"10.1016\/j.prp.2021.153677_bib20","first-page":"669","article-title":"Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin)","volume":"37","author":"Oliveras-Ferraros","year":"2010","journal-title":"Int J. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2021.153677_bib21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4161\/cc.23274","article-title":"Basal\/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)","volume":"12","author":"Martin-Castillo","year":"2013","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.prp.2021.153677_bib22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","article-title":"HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial","volume":"18","author":"Llombart-Cussac","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.prp.2021.153677_bib23","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1200\/JCO.2014.56.2439","article-title":"Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial","volume":"33","author":"Pogue-Geile","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2021.153677_bib24","doi-asserted-by":"crossref","first-page":"djw207","DOI":"10.1093\/jnci\/djw207","article-title":"Intrinsic subtype and therapeutic response among HER2-positive breaty st tumors from the NCCTG (Alliance) N9831 trial","volume":"109","author":"Perez","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.prp.2021.153677_bib25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4143\/crt.2018.342","article-title":"Discordance of the PAM50 intrinsic subtypes compared with immunohistochemistry-based surrogate in breast cancer patients: potential implication of genomic alterations of discordance","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res Treat."},{"issue":"8","key":"10.1016\/j.prp.2021.153677_bib26","doi-asserted-by":"crossref","first-page":"dju152","DOI":"10.1093\/jnci\/dju152","article-title":"Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer","volume":"106","author":"Prat","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"14 Pt 1","key":"10.1016\/j.prp.2021.153677_bib27","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1158\/1078-0432.CCR-06-0353","article-title":"Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer","volume":"12","author":"Laakso","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2021.153677_bib28","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.clbc.2015.06.001","article-title":"Basal protein expression is associated with worse outcome and trastuzamab resistance in HER2+ invasive breast cancer","volume":"15","author":"Chung","year":"2015","journal-title":"Clin. Breast Cancer"},{"issue":"3","key":"10.1016\/j.prp.2021.153677_bib29","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10549-018-4873-0","article-title":"Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03","volume":"171","author":"Sagara","year":"2018","journal-title":"Breast Cancer Res Treat."},{"issue":"7418","key":"10.1016\/j.prp.2021.153677_bib30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.prp.2021.153677_bib31","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1158\/1078-0432.CCR-13-2943","article-title":"TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance","volume":"20","author":"Silwal-Pandit","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2021.153677_bib32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clbc.2019.09.003","article-title":"Clinicopathologic factors associated with response to neoadjuvant anti-HER2-Directed chemotherapy in HER2-Positive breast cancer","volume":"20","author":"Meisel","year":"2020","journal-title":"Clin. Breast Cancer"},{"issue":"3","key":"10.1016\/j.prp.2021.153677_bib33","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-021-06287-4","article-title":"Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers","volume":"189","author":"Savas","year":"2021","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.prp.2021.153677_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ctrv.2017.04.005","article-title":"Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials","volume":"57","author":"Solinas","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"7","key":"10.1016\/j.prp.2021.153677_bib35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2021.153677_bib36","unstructured":"WHO classification of tumours editorial board (2019) Breast tumours. International agency for research on cancer. \u3008https:\/\/publications.iarc.fr\/581\u3009."},{"issue":"9","key":"10.1016\/j.prp.2021.153677_bib37","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2021.153677_bib38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","article-title":"Breast cancer immunotherapy: facts and hopes","volume":"24","author":"Emens","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2021.153677_bib39","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr2868","article-title":"Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo","volume":"13","author":"Barok","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.prp.2021.153677_bib40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.18632\/oncotarget.488","article-title":"Metformin-induced preferential killing of breast cancer initiating CD44+CD24-\/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts","volume":"3","author":"Cufi","year":"2012","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.prp.2021.153677_bib41","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1186\/bcr2899","article-title":"Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes","volume":"13","author":"Gatza","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"21","key":"10.1016\/j.prp.2021.153677_bib42","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.4161\/cc.22225","article-title":"Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)","volume":"11","author":"Oliveras-Ferraros","year":"2012","journal-title":"Cell Cycle"},{"issue":"32","key":"10.1016\/j.prp.2021.153677_bib43","doi-asserted-by":"crossref","first-page":"32317","DOI":"10.18632\/oncotarget.6094","article-title":"Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas","volume":"6","author":"Martin-Castillo","year":"2015","journal-title":"Oncotarget"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033821003381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033821003381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:48:44Z","timestamp":1759733324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033821003381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":43,"alternative-id":["S0344033821003381"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2021.153677","relation":{},"ISSN":["0344-0338"],"issn-type":[{"type":"print","value":"0344-0338"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2021.153677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"153677"}}